Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
FDA: Management of chronic stable angina (vasospastic and exertional), treatment of hypertension.
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
2-4 hours (terminal); prolonged in hepatic impairment; clinical context: requires continuous IV infusion for sustained effect
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism. Metabolites are inactive.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal: 55-60% as metabolites, <1% unchanged; biliary/fecal: 35-40%
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
>95% bound to albumin, alpha-1-acid glycoprotein, and lipoproteins
Approximately 90% bound to plasma proteins, primarily albumin.
0.2-0.6 L/kg; suggests limited tissue distribution; higher in hepatic cirrhosis
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
IV: 100%; not available orally in this formulation
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
GFR < 30 m L/min: initial dose 2.5 mg/hr; titrate cautiously. No adjustment for GFR ≥ 30.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh Class A: no adjustment. Class B: reduce initial dose by 50%. Class C: avoid use.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and efficacy not established; no standard dosing recommendations.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Start at lower end of dosing range (2.5-3 mg/hr); titrate slowly due to increased sensitivity.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
None.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Hypotension and reflex tachycardia may occur, especially in patients on beta-blockers.,Use caution in patients with congestive heart failure or impaired ventricular function.,May cause worsening of angina on abrupt withdrawal.,Hepatic impairment may increase drug levels; dose adjustment may be needed.,Peripheral edema is common but not due to fluid retention.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to nicardipine or any component of the formulation.,Advanced aortic stenosis.
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice as they may increase nicardipine levels. High fat meals can affect absorption, but since this is IV, dietary restrictions primarily relate to dextrose content for diabetics. No other significant food interactions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, and growth restriction due to maternal hypotension; avoid use for tocolysis.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Nicardipine is excreted in human milk; estimated infant dose <2% of maternal weight-adjusted dose. M/P ratio: 1.2. Caution advised; monitor infant for hypotension and cardiovascular effects.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No specific dose adjustment required based on pharmacokinetic changes; use lowest effective dose; monitor for maternal hypotension and fetal effects.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
CARDENE (nicardipine) in 4.8% dextrose is a dihydropyridine calcium channel blocker used for IV treatment of hypertension. It is light-sensitive; protect from light. Titrate dose by 1-2 mg/hour increments every 5 minutes up to target blood pressure. Do not mix with sodium bicarbonate or lactated Ringer's. Use with caution in patients with coronary artery disease due to reflex tachycardia, and in hepatic impairment as metabolism is hepatic. May cause peripheral edema; monitor for worsening heart failure.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
This medication is given intravenously to lower blood pressure; you will be closely monitored.,Inform your healthcare provider if you have a history of heart disease, liver problems, or if you are pregnant or breastfeeding.,You may experience headache, dizziness, or flushing; report these if severe.,Avoid alcohol consumption while on this medication as it may increase side effects.,This solution contains dextrose; notify your doctor if you have diabetes or need to restrict sugar intake.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER vs CALAN, answered by our medical review team.
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is a Calcium Channel Blocker that works by Calcium channel blocker (dihydropyridine type) that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and decreased myocardial contractility.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is: Intravenous: 5 mg/hr initially, titrate by 2.5 mg/hr every 15 minutes based on response; usual maintenance 3-10 mg/hr.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER is classified as Category C. First trimester: No adequate human studies; animal studies show no teratogenic effects at therapeutic doses. Second and third trimesters: Potential for fetal hypoxia, hypotension, . CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.